
Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Stock analysts at Zacks Research cut their Q2 2025 EPS estimates for shares of Nektar Therapeutics in a report released on Monday, June 30th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings of ($2.83) per share for the quarter, down from their previous estimate of ($0.19). The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share. Zacks Research also issued estimates for Nektar Therapeutics' Q3 2025 earnings at ($2.85) EPS, Q4 2025 earnings at ($2.86) EPS, Q1 2026 earnings at ($3.03) EPS, Q2 2026 earnings at ($3.59) EPS, Q3 2026 earnings at ($4.00) EPS, Q4 2026 earnings at ($4.10) EPS, FY2026 earnings at ($14.72) EPS, Q1 2027 earnings at ($3.92) EPS, Q2 2027 earnings at ($4.46) EPS and FY2027 earnings at ($18.57) EPS.
A number of other equities analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of Nektar Therapeutics from a "hold" rating to a "sell" rating in a research note on Wednesday, May 14th. BTIG Research boosted their target price on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the stock a "buy" rating in a research note on Tuesday, June 24th. William Blair reaffirmed a "market perform" rating on shares of Nektar Therapeutics in a research note on Monday, May 12th. HC Wainwright boosted their target price on shares of Nektar Therapeutics to $120.00 and gave the stock a "buy" rating in a research note on Tuesday, June 24th. Finally, Oppenheimer raised shares of Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $90.00 target price for the company in a research note on Friday, March 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Nektar Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $84.17.
View Our Latest Report on NKTR
Nektar Therapeutics Stock Down 3.4%
NASDAQ:NKTR traded down $0.88 on Wednesday, reaching $24.65. The stock had a trading volume of 994,109 shares, compared to its average volume of 477,427. The company has a market capitalization of $305.91 million, a P/E ratio of -2.57 and a beta of 0.94. Nektar Therapeutics has a 1-year low of $6.48 and a 1-year high of $37.38. The stock has a fifty day moving average price of $12.97 and a 200-day moving average price of $12.55.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) EPS for the quarter, missing analysts' consensus estimates of ($2.70) by ($0.60). The firm had revenue of $10.46 million during the quarter, compared to analyst estimates of $15.61 million. Nektar Therapeutics had a negative net margin of 152.49% and a negative return on equity of 329.54%. During the same quarter last year, the firm earned ($2.70) earnings per share.
Institutional Investors Weigh In On Nektar Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. Squarepoint Ops LLC bought a new stake in shares of Nektar Therapeutics during the fourth quarter worth approximately $130,000. Wellington Management Group LLP increased its stake in Nektar Therapeutics by 10.4% in the fourth quarter. Wellington Management Group LLP now owns 522,409 shares of the biopharmaceutical company's stock valued at $486,000 after purchasing an additional 49,319 shares in the last quarter. D. E. Shaw & Co. Inc. increased its stake in Nektar Therapeutics by 267.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 175,193 shares of the biopharmaceutical company's stock valued at $163,000 after purchasing an additional 127,459 shares in the last quarter. Rhumbline Advisers increased its stake in Nektar Therapeutics by 23.3% in the first quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company's stock valued at $151,000 after purchasing an additional 41,948 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its stake in Nektar Therapeutics by 32.8% in the fourth quarter. Ameriprise Financial Inc. now owns 373,948 shares of the biopharmaceutical company's stock valued at $348,000 after purchasing an additional 92,346 shares in the last quarter. 75.88% of the stock is owned by institutional investors.
Nektar Therapeutics Company Profile
(
Get Free Report)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
Recommended Stories

Before you consider Nektar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.
While Nektar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.